Quantcast

Latest Inflammatory bowel disease Stories

2014-03-12 08:30:38

The Jeffrey Epstein VI Foundation funds groundbreaking research to prevent Crohns and Colitis Disease. NEW YORK, March 12, 2014 /PRNewswire/ -- Crohns and Colitis Disease is a chronic disease of the lower intestinal track, causing inflammation and a host of crippling symptoms from ulcers to intestinal rupture. The disease affects approximately 700,000 Americans and many more suffer from undiagnosed irritable bowel syndrome. To date, not much is known about the ultimate cause of...

2014-03-11 16:26:53

ATLANTIC CITY, N.J., March 11, 2014 /PRNewswire/ -- A jury in New Jersey returned a $1.59 million verdict to a former Accutane user against N.J.-based pharmaceutical companies Hoffmann La-Roche Inc. and Roche Laboratories. The plaintiff, Kamie Kendall Rees, was prescribed several courses of Accutane for treatment of her acne in the 1990s, starting at the age 12. Shortly thereafter, Ms. Kendall Rees developed ulcerative colitis--a permanent, debilitating disease. Unable to manage...

2014-03-10 16:31:55

Foundation Champions Innovation & Collaboration to Accelerate IBD Breakthroughs OAKLAND, Calif., March 10, 2014 /PRNewswire-USNewswire/ -- The Kenneth Rainin Foundation's 2014 Innovations Symposium: Taming the Microbiome will take place July 15 - 16, 2014, at the Union Square Marriott in San Francisco. The annual event brings together influential and collaborative researchers and institutions, with the common goal of curing Inflammatory Bowel Disease (IBD), a disease that affects...

2014-03-04 23:26:41

With locations in Phoenix and Mesa, Arizona, The Giving Tree Wellness Center provides a holistic approach to pain relief and well-being. They are thrilled to support the Take Steps for Crohn's & Colitis fundraising event on March 29, 2014. Phoenix, AZ (PRWEB) March 04, 2014 At the heart of alternative healing is a holistic approach and strong community. The Giving Tree Wellness Center has locations in Mesa and Phoenix, and focuses largely on pain management for those tackling...

2014-03-03 08:32:34

CCFA Researchers Map Out Strategies to New Drugs and Individualized Therapy for Crohn's Disease and Ulcerative Colitis NEW YORK, March 3, 2014 /PRNewswire/ -- High-powered research teams supported by the Crohn's & Colitis Foundation of America (CCFA) are gearing up for an ambitious new goal: developing individualized treatment approaches for patients with Crohn's disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD), through their Genetics and...

2014-02-26 08:28:31

OKLAHOMA CITY, Feb. 26, 2014 /PRNewswire/ -- Altheus Therapeutics, Inc., announced completion of dosing in ZA201, a double-blind, active-controlled Phase 2 trial evaluating the efficacy and safety of Zoenasa® Rectal Gel versus mesalamine enema in 120 patients with left-sided ulcerative colitis. The primary endpoint of ZA201 is reduction in the Ulcerative Colitis Disease Activity Index (UCDAI) at 6 weeks. Secondary endpoints include endoscopic remission, reduction in UCDAI at 3...

2014-02-04 04:21:48

LONDON, February 4, 2014 /PRNewswire/ -- Shield Therapeutics (Shield), an independent specialty pharmaceutical company, today announces the acceptance of the first peer-reviewed abstract relating to data from the AEGIS Phase III programme of ST10 for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD). The data will be presented at the 9th Congress of ECCO, taking place from February 20 - 22 in Copenhagen, Denmark. As recently announced,...

2014-01-29 12:27:38

OKLAHOMA CITY, Jan. 29, 2014 /PRNewswire/ -- Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine). Combination therapy patents are uncommon and under-appreciated in the pharmaceutical industry because the Patent Office requires surprising, unexpected, or synergistic benefits from combining active ingredients into a single formulation. Altheus' success in...

2014-01-16 16:24:09

AUSTIN, Texas, Jan. 16, 2014 /PRNewswire/ -- XBiotech announced today that it has launched a Phase II study to treat a rare but debilitating disorder, Pyoderma Gangrenosum (PG). This study is based on efficacy seen with anti-IL-1 therapeutic antibody in previous dermatological clinical studies such as psoriasis and acne. PG is expected to be considered an "orphan indication" by the FDA, facilitating expedited clinical development to market. Dr. Armand Cognetta, lead clinical...

2014-01-15 08:29:25

Collaboration Brings Unique Expertise Together THOUSAND OAKS, Calif., Jan. 15, 2014 /PRNewswire/ -- Massachusetts General Hospital (MGH), the Broad Institute, and Amgen (NASDAQ:AMGN) announced today that they have launched a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration brings together...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.